Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Via News Knowledge File

AstraZeneca AB

organization80% conf.·synced Aug 13, 2026

Pharmaceutical company with license agreement with Insmed

57
sourced metrics
409
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Revenue
30595USD
Jul 27, 2026source
Eps
1.61USD
Jul 27, 2026source
Dividend Per Share
1.06USD
Jul 27, 2026source
Stock Price
168.90USD
Jul 17, 2026source
Stock Return 30day
5.2percent
Apr 1, 2026source
Stock Return 1year
54.8percent
Apr 1, 2026source
Free Cash Flow
9.49USD
Apr 1, 2026source
Stock Return Ytd
12.1percent
Apr 1, 2026source
Projected Free Cash Flow
20.16USD
Apr 1, 2026source
Valuation Score
3out_of_6
Apr 1, 2026source
Intrinsic Value Dcf
238.68USD
Apr 1, 2026source
Stock Return 7day
-0.6percent
Apr 1, 2026source
Marathon Holding Value
12.85USD
Mar 31, 2026source
Marathon Holding Pct Aum
2.9percent
Mar 31, 2026source
Return 1year
21.8percent
Mar 1, 2026source
Analyst Price Target
165.33GBP
Mar 1, 2026source
Free Cash Flow Projected
20.2USD
Mar 1, 2026source
Intrinsic Value Per Share
242.86GBP
Mar 1, 2026source

Stated objectives

Reach $80bn in annual sales by 2030

source
target: 80 billion USD by 2030-01-01 00:00:00stated

Achieve operating margin in mid-thirties percent range

source
target: 35 percent stated

High single digit revenue growth for 2025 on constant currency basis

source
target: 7-9 percent by 2025-01-01 00:00:00stated

Low double digit growth in adjusted earnings per share for 2025 on constant currency basis

source
target: 10-12 percent by 2025-01-01 00:00:00stated

Increase total revenue by mid-to-high single-digit percentage for FY 2026 at constant exchange rates

source
target: mid-to-high single-digit percentage growth by 2026-12-31 00:00:00stated

Increase core EPS by low double-digit percentage for FY 2026 at constant exchange rates

source
target: low double-digit percentage growth by 2026-12-31 00:00:00stated

Invest $15 billion in China through 2030 to expand medicines manufacturing and R&D

source
target: $15 billion by 2030-12-31 00:00:00stated

Complete more than 20 Phase 3 trial readouts in 2026

source
target: 20+ Phase 3 readouts by 2026-12-31 00:00:00stated

Obtain FDA approval for baxdrostat as first-in-class aldosterone synthase inhibitor for hard-to-control hypertension

source
target: regulatory approval stated

Advance portfolio of medicines for organ protection by slowing or stopping disease progression, paving way towards regenerative therapies in CVRM

source
stated

Relationship graph · 409 connections

Developed by
145
Competes with
73
Employs
25
Partnered with
21
located in
13
headquartered in
12
contracted by
10
acquired by
10
Invested in
Greater China
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →